Description
FPV-CV301 is an investigational vaccine being studied in clinical trials for specific types of metastatic colorectal cancer (CRC). It is being investigated in combination with other treatments like chemotherapy (mFOLFOX6), another investigational vaccine (MVA-BN-CV301), and immunotherapy (Nivolumab). The trial focuses on patients with liver-limited metastatic CRC who are candidates for surgery after initial treatment. The goal is to see if this vaccine approach, given before and after potential surgery, can improve outcomes by stimulating the body's immune system to fight the cancer. The vaccine is designed to target the cancer cells specifically. It is currently being studied in Phase 2 trials.
Mechanism of Action
FPV-CV301 is a type of cancer vaccine. Vaccines work by teaching the body's immune system to recognize and attack specific targets, like cancer cells. This vaccine is designed to stimulate an immune response against the patient's own colorectal cancer cells. The specific way it works (the exact molecular target or mechanism) is being investigated in clinical trials. It is given in multiple doses, both before and after potential surgery, along with other standard treatments.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.